Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 312 for Lung cancer

Edit search filters
  1. A Study to Assess the Effectiveness, Safety, and Drug/Body Interactions of Rovalpituzumab for Third-Line and Later Treatment of Patients with Small Cell Lung Cancer that has Returned or is Resistant to Treatment

    Rochester, MN

  2. A Study to Compare Radiation Therapy + Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer

    Albert Lea, MN, Scottsdale/Phoenix, AZ, La Crosse, WI, Rochester, MN

  3. A Study of Rociletinib (CO-1686) for Patients with a Mutant form of Non-Small Cell Lung Cancer.

    Scottsdale/Phoenix, AZ

  4. A Study Using Avelumab in Non-Small Cell Lung Cancer that has Progressed

    Scottsdale/Phoenix, AZ

  5. Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

    Rochester, MN

  6. PKCι & mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer

    Jacksonville, FL, Scottsdale/Phoenix, AZ

  7. A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer

    Rochester, MN

  8. Neoadjuvant dual checkpoint blockade with PD1 and LAG-3 inhibition in resectable Non-small cell lung Cancer

    Rochester, MN

  9. A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants

    Scottsdale/Phoenix, AZ, Rochester, MN

  10. Synergy with Grid Therapy and Immune Checkpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer

    Rochester, MN

.

Mayo Clinic Footer